![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, August 10, 2017 11:48:11 AM
I think there is large upside potential from the bottom, but who knows where the bottom is? If they have to raise more money, it could be much lower from the current price.
I think they should make a deal on Glucophage and Keppra at break-even just so they can take advantage of the cashflow. That may be very minimal, I don't know what the market is like for those two.
I don't think it's worth trying to hold $1 just to not get delisted. Odidi would probably be better off finding financing and taking it private or selling the whole thing to IPXL or another generic player (with no or few overlapping products). I don't think it will go for $11/sh, now. Maybe $3.
The FDA really screwed them over, but Odidi has not helped matters.
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM